Transaction Details
NATCO Pharma Limited successfully completed acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited, a leading South African pharmaceutical and healthcare company. The transaction was completed through NATCO Pharma South Africa Proprietary Limited, NATCO's wholly owned subsidiary in South Africa.
Financial Details
The acquisition involved aggregate consideration of approximately ZAR 1.81 billion, equivalent to approximately ₹1,060 crores at the transaction exchange rate.
Ownership Impact
Post-transaction, NATCO's shareholding in Adcock Ingram increased from 35.75% to 49%.
Transaction Timeline and Background
NATCO first acquired 35.75% in Adcock Ingram through participation in Adcock Ingram's delisting process in 2025, following announcement of firm intention offer in July 2025, shareholder approval in October 2025, and completion in November 2025. NATCO's Board approved the additional 13.25% stake acquisition in July 2026. The transaction completed following satisfaction of customary closing conditions and regulatory requirements.
Company Information - NATCO Pharma
NATCO Pharma Limited is listed on BSE (Scrip Code: 524816) and NSE (Scrip Code: NATCOPHARM) with market capitalization of approximately US$1.82 billion. Established in 1981, the company focuses on pharmaceutical R&D with emphasis on oncology, cardiology, neurology, and other high-value therapeutic categories. The company operates 9 manufacturing facilities certified by US FDA, Brazil's ANVISA, Health Canada, and WHO, and exports to more than 50 countries.
Company Information - Adcock Ingram
Adcock Ingram is a South African pharmaceutical company established in 1891, ranked 2nd in private and public pharmaceutical market in South Africa. The company manufactures, markets, and distributes healthcare products to both private and public sectors, with portfolio including Prescription, OTC, Consumer and Hospital products. The company holds 10% market share of private market, is leader in OTC pharmaceutical market, and is largest supplier of hospital and critical care products in South Africa. Manufacturing facilities include three in South Africa and two in India.